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Abstract
Background. Proteinuria is a cardinal feature of
glomerular disease, including diabetic nephropathy,
and the glomerular ﬁltration barrier acts as a ﬁlter,
restricting protein excretion in urine. We tested
whether the expression of P-cadherin, a molecule
known to be located at the slit diaphragm, was altered
by diabetes in vivo and by high glucose in vitro.
Methods. In vivo, 24 Sprague–Dawley rats were
injected with diluent [control (C), n¼ 8] or strepto-
zotocin intraperitoneally and the latter were left
untreated (DM, n¼ 8) or treated with insulin (DMþ I,
n¼ 8) for 6 weeks. In vitro, immortalized mouse
podocytes were cultured in media with 5.6mM glucose
(LG), LGþ 19.4mM mannitol (LGþM) or 25mM
glucose (HG) with or without protein kinase C
(PKC) inhibitor (107M calphostin C or 106M GF
109203X). Reverse transcription–polymerase chain
reaction, western blotting for P-cadherin mRNA and
protein expression, respectively, were performed with
sieved glomeruli and cell lysates, and immunoﬂuores-
cence staining was undertaken with renal tissue.
Results. Twenty-four hour urinary albumin excretion
was signiﬁcantly higher in DM compared with C
and DMþ I rats (P<0.05). Glomerular P-cadherin
mRNA expression was signiﬁcantly lower in
DM (1.36±0.20 102 attm/ng RNA) than in
C rats (2.61±0.33 102 attm/ng RNA) (P<0.05).
P-Cadherin protein expression, assessed by western
blot and immunoﬂuorescence staining, was also
decreased in DM compared with C and DMþ I
glomeruli. HG signiﬁcantly reduced P-cadherin
mRNA and protein expression in cultured podocytes
by 42% and 62%, respectively (P<0.05), and these
decrements were ameliorated by PKC inhibitor.
Conclusions. Diabetes in vivo and exposure of podo-
cytes to HG in vitro reduced P-cadherin mRNA
and protein expression, and PKC was involved in
the regulation of HG-induced down-regulation of
P-cadherin. These ﬁndings suggest that the decrease
in P-cadherin expression is connected with the early
changes of diabetic nephropathy and, thus, may
contribute to the development of proteinuria.
Keywords: P-cadherin; diabetic nephropathy;
high glucose; podocyte; proteinuria
Introduction
Diabetic nephropathy, the leading cause of end-stage
renal disease in the USA [1], is clinically characterized
by proteinuria. The underlying pathological change
responsible for proteinuria in various glomerular
diseases, including diabetic nephropathy, is the loss of
size-selective and/or charge-selective properties of the
glomerular ﬁltration barrier. The glomerular ﬁltration
barrier is comprised of three layers: a fenestrated
endothelial layer, the glomerular basement membrane
(GBM) and podocyte foot processes connected by
a slit diaphragm. Traditionally, the GBM has been
considered a coarse ﬁlter restricting large molecules,
while the slit diaphragm was thought to function as a
ﬁne ﬁlter contributing ultimate size-selectivity, per-
mitting permeability only to molecules smaller than
albumin [2].
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The slit diaphragm, which bridges adjacent foot
processes derived from different podocytes, is a
continuous ﬁlamentous structure containing pores of
414 nm. In the past, the slit diaphragm was con-
sidered a modiﬁed tight junction due to the presence of
the tight junction protein, zonula occludens-1, at the
cytoplasmic side of the slit diaphragm [3]. However,
recent studies using immunoﬂuorescence and immuno-
electron microscopy revealed that the slit diaphragm is
a modiﬁed adherens junction rather than a modiﬁed
tight junction and that P-cadherin was localized at the
slit diaphragm [4]. In addition to P-cadherin, nephrin,
NEPH1 and FAT are located in the slit diaphragm
region [5].
Cadherins are a superfamily of glycoproteins that
mediate Ca2þ-dependent, homotypic cell–cell adhesion
in all solid tissues of the organism [6]. They are known
to play important roles in maintaining the structural
integrity of epithelial tissues and in tissue morpho-
genesis and to serve as signalling molecules to regulate
cell behaviour, especially in some kinds of tumours. The
classical cadherins are the best characterized members
of the family and are designated by the originally
described tissue speciﬁcity, including E- (epithelial),
N- (neural) and P- (placental) cadherins [6]. E-Cadherin
is expressed in most epithelial cells, whereas P-cadherin
is restricted to basal cell layers, including basal cells
of skin and prostate and myoepithelial cells of the
mammary gland. Cadherins E and P have also been
demonstrated in glomeruli [4,7], but their precise
functions in the normal state and their changes in
glomerulopathy have been explored less thoroughly. A
recent study revealed that E-cadherin was expressed
more frequently in glomerular epithelial cells and its
expression in podocytes was slightly increased in
patients with proliferative glomerulonephritis [7].
P-Cadherin is known to serve as a basic scaffold for
the slit diaphragm, whereas the permselectivity is
provided by the slit diaphragm complex composed of
P-cadherin and other proteins, such as nephrin [4].
To investigate the pathogenesis of proteinuria in
diabetic nephropathy, we tested whether the expression
of P-cadherin was altered by diabetes in vivo and by
high glucose in cultured podocytes in vitro. In addition,
we determined whether protein kinase C (PKC), which
is known to be activated under diabetic conditions
in numerous cells, was involved in the changes in
P-cadherin expression. In the current study, P-cadherin
mRNA and protein levels were measured in glomeruli
from streptozotocin-induced diabetic rats and in con-
ditionally immortalized mouse podocytes cultured
under high-glucose conditions.
Subjects and methods
Animals
All animal studies were conducted under a protocol approved
by the committee for the care and use of laboratory animals
of Yonsei University College of Medicine. Twenty-four male
Sprague–Dawley rats, weighing 230–270 g, were studied.
Eight were injected with diluent [control (C)] and 16 were
injected with 65mg/kg streptozotocin intraperitoneally.
Blood glucose levels were measured on the third day after
streptozotocin injection to conﬁrm the development of
diabetes. Diabetic rats were then randomly assigned to two
groups. One group (n¼ 8) was treated with 2U/day of
Humulin (Ultralente; Eli Lilly Co., Indianapolis, IN, USA)
(DMþ I) and the remaining eight diabetic rats were left
untreated (DM) to examine the effect of diabetes per se. In a
previous study [8], diabetic rats without insulin were able to
be maintained in good condition up to 4 months by keeping
each rat in a separate cage and by changing cages every day.
All rats were housed in a temperature-controlled room
with free access to water and standard laboratory chow and
were sacriﬁced after 6 weeks. When we measured the urinary
albumin excretion in diabetic rats, a statistically signiﬁcant
increase in urinary albumin excretion was observed for the
ﬁrst time at 6 weeks after streptozotocin injection. Since
the purpose of this study was to examine the changes of
P-cadherin expression in a point of albuminuria, we used
6-week-old diabetic rats.
Body weights were checked weekly and kidney weights
measured at the time of sacriﬁce. Serum glucose and 24 h
urinary albumin also were measured at the time of sacriﬁce.
Blood glucose was measured by glucometer and 24 h urinary
albumin excretionwas determined by enzyme-linked immuno-
sorbent assay (Nephrat II; Exocell, Inc., Philadelphia,
PA, USA).
Podocyte culture
Conditionally immortalized mouse podocytes were kindly
provided by Dr Peter Mundel (Albert Einstein College of
Medicine, Bronx, NY, USA) and were cultured as described
previously [9]. Brieﬂy, frozen podocytes were ﬁrst grown
under permissive conditions at 33C in RPMI 1640 media
containing 10% fetal bovine serum, 50U/ml g-interferon
and 100U/ml of penicillin/streptomycin in collagen-coated
ﬂasks and the g-interferon was tapered down to 10U/ml in
successive passages. Cells were then trypsinized and sub-
cultured without g-interferon (non-permissive conditions) and
allowed to differentiate at 37C with media changed on alter-
nate days. Differentiation of podocytes at 37Cwas conﬁrmed
by the identiﬁcation of synaptopodin, a podocyte differentia-
tion marker, using reverse transcription–polymerase chain
reaction (RT–PCR) and western blotting (data not shown).
After conﬁrming differentiation of podocytes, medium
was changed to RPMI medium containing normal glucose
(5.6mM; LG), LGþ 19.4mM mannitol (LGþM; to achieve
isoosmolality) or high glucose (25mM; HG) with or without
6 h pre-treatment of PKC inhibitor (107M calphostin C
or 106M GF 109203X; Calbiochem, San Diego, CA, USA).
After 3 days, cells were harvested for either RNA or protein.
Total RNA extraction
Glomeruli were isolated by sieving. The purity of the
glomerular preparation was >98%, as determined by light
microscopy. Total RNA was extracted as described pre-
viously [8]. Brieﬂy, addition of 100ml RNA STAT-60 reagent
(Tel-Test, Inc., Friendswood, TX, USA) to the glomeruli was
followed by glomerular lysis by freezing and thawing three
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times. Another 700ml RNA STAT-60 reagent was added,
the mixture vortexed and stored for 5min at room tempera-
ture; then, 400 ml chloroform was added and the mixture
shaken vigorously for 30 s. After 3min, the mixture was
centrifuged at 12 000 g for 15min at 4C and the upper
aqueous phase containing the extracted RNA was transferred
to a new tube. RNA was precipitated from the aqueous phase
by 400 ml isopropanol and pelleted with centrifugation at
12 000 g for 30min at 4C. The RNA precipitate was washed
with 70% ice-cold ethanol, dried using Speed Vac and
dissolved in DEPC-treated distilled water. RNA from
podocytes was extracted similarly. Glomerular and podocyte
RNA yields and quality were assessed based on spectro-
photometric measures at 260 and 280 nm.
Reverse transcription
First strand cDNA was made by utilizing a Boehringer
Mannheim cDNA synthesis kit (Boehringer Mannheim
GmbH, Mannheim, Germany). Two mg of total RNA
extracted from sieved glomeruli was reverse transcribed
using 10 mM random hexanucleotide primer, 1mM dNTP,
8mM MgCl2, 30mM KCl, 50mM Tris–HCl (pH 8.5),
0.2mM dithiothreitol, 25U RNase inhibitor and 40U
AMV reverse transcriptase. The mixture was incubated at
30C for 10min and 42C for 1 h, followed by inactivation
of the enzyme at 99C for 5min. Podocyte RNA from each
plate was similarly reverse transcribed.
Polymerase chain reaction
The primers used for rat and mouse GAPDH were as follows:
rat sense, 50-GACAAGATGGTGAAGGTCGG-30, anti-
sense 50-CATGGACTGTGGTCATGAGC-30; mouse sense,
50-CCTGCACCACCAACTGCTTAGC-30, antisense 50-CC
AGTGAGCTTCCCGTTCAGC-30. Since the rat P-cadherin
mRNA sequence has not been reported in GenBank, a partial
sequence of rat P-cadherin mRNA was sequenced from the
PCR product using cDNA of rat glomeruli and primers
designed on the area where human and mouse P-cadherin
showed homology (sense 50-CTTCTGTGATGCAGGTGAC
AG-30, antisense 50-GCCTCAAAATCCAAACCCTTC-30).
Then, new rat and mouse P-cadherin primers were designed
as follows: rat sense 50-CTTACAATGGGGTGGTGG-30,
antisense 50-GCCACGGTGAAATGATCC-30; mouse sense
50-CTTACAATGGGGTGGTGG-30, antisense 50-GTGAT
GGTGAAATGGTCC-30. The cDNAs from 10ng RNA of
glomeruli and podocytes per reaction tube were used for
GAPDH and 50 ng RNA of glomeruli and 20 ng RNA of
podocytes for P-cadherin.
For GAPDH and P-cadherin mRNA expression, we used
quantitative competitive PCR. The competitor cDNA was
used as internal standard and was designed to contain the
same base-pair sequence as the target cDNA that would
allow efﬁcient priming, but with a portion deleted so that
the competitor PCR-generated fragment could easily be
distinguished electrophoretically by size. The RT–PCR
products were separated by electrophoresis, the band
densities analysed by TINA image software (Raytest,
Straubenhardt, Germany), the values log transformed and
a log-linear regression analysis was performed against the
competitor concentration for each PCR tube. The quantity
of cDNA in the test sample was deﬁned as the amount at
which the competitor and wild-type optical density bands
were equal. PCR was performed using cDNA, 1.25U
TaqGold polymerase, 20mM dNTP and 25 pmol sense and
antisense primers in a volume of 50ml containing 1 PCR
buffer. The PCR conditions were as follows: GAPDH,
35 cycles, denaturation at 95C for 45 s, annealing at 60C
for 45 s and extension at 72C for 1min; and P-cadherin, 45
cycles for glomeruli and 42 cycles for podocytes, denaturation
at 95C for 45 s, annealing at 58C for 45 s and extension at
72C for 1min. Initial heating at 95C for 9min and ﬁnal
extension at 72C for 7min was performed for all PCRs.
Western blot analysis
Sieved glomeruli and podocytes harvested from plates were
lysed in sodium dodecyl sulphate (SDS) sample buffer
[2% SDS, 10mM Tris–HCl, pH 6.8, 10% (vol/vol) glycerol].
Lysate was centrifuged at 10 000 g for 10min at 4C and the
supernatant was stored at 70C until all rats were sacriﬁced.
Protein concentrations were determined with a Bio-Rad
kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Aliquots of 50mg protein were treated with Laemmli
sample buffer, then heated at 100C for 5min and electro-
phoresed (50 mg/lane) in an 8% acrylamide denaturing
SDS–polyacrylamide gel. Proteins were transferred to
Hybond–ECL membrane (Amersham Life Science, Inc.,
Arlington Heights, IL, USA) using a Hoeffer semi-dry
blotting apparatus (Hoeffer Instruments, San Francisco,
CA, USA), the membrane incubated in blocking buffer A
(1 PBS, 0.1% Tween-20 and 8% non-fat milk) for 1 h at
room temperature and then incubated overnight at 4Cwith a
1:500 dilution of monoclonal anti-P-cadherin antibody
(Zymed Laboratories, Inc., San Francisco, CA, USA). The
membrane was washed once for 15min and twice for 5min
in 1 PBS with 0.1% Tween-20 and incubated in buffer A
with horseradish peroxidase-linked sheep anti-mouse IgG
(Amersham Life Science, Inc., Arlington Heights, IL, USA)
at 1:1000 dilution. The washes were repeated and the
membrane developed with chemiluminescent agent (ECL;
Amersham Life Science, Inc., Arlington Heights, IL, USA).
Pathology
Slices of kidney for immunoﬂuorescence staining were ﬁxed
in 10% neutral buffered formalin, processed in the standard
manner and 5-mm sections of parafﬁn embedded tissues were
utilized. Slides were deparafﬁnized, hydrated in ethyl alcohol
and washed in tap water. Antigen retrieval was carried out in
10mM sodium citrate buffer for 20min using a Black and
Decker vegetable steamer. For P-cadherin staining, mono-
clonal anti-P-cadherin antibody (Zymed Laboratories, Inc.,
San Francisco, CA, USA) was diluted 1:200 with 2% casein in
bovine serum albumin (BSA) and was applied for overnight
incubation at room temperature. After washing, a secondary
rhodamine red-X-conjugated goat anti-rat IgG (Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) was
added for 60min. A semi-quantitative score for measuring
P-cadherin immunoﬂuorescence intensity within glomeruli
was determined by examining 30 glomeruli in each section
and by digital image analysis (MetaMorph version 4.6r5;
Universal Imaging Corp., Downingtown, PA, USA). To
conﬁrm that the change of P-cadherin expression was not due
to the change of podocyte numbers, immunohistochemical
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staining for Wilms’ tumour-1 protein (WT-1) was also done.
A rabbit polyclonal antibody to WT-1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) was diluted in
1:100 with 2% casein in BSA and was applied for overnight
incubation at room temperature. After washing, a secondary
goat anti-rabbit antibody was added for 20min, the slides
were washed and incubated with a tertiary rabbit–PAP
complex for 20min. DAB was added for 2min and the
slides were counterstained with haematoxylin. All cells
stained positive for WT-1 in 20 glomeruli cut at the vascular
pole were considered as podocytes and were counted to
conﬁrm the change of podocyte numbers.
Statistical analysis
All values are expressed as means±SEM. Statistical analysis
was performed using the statistical package SPSS for
Windows v. 7.51 (SPSS, Inc., Chicago, IL, USA). Results
were analysed using the Kruskal–Wallis non-parametric test
for multiple comparisons. If there was a signiﬁcant difference
by the Kruskal–Wallis test, it was conﬁrmed further by the
Mann–Whitney U-test. Statistical signiﬁcance was deter-
mined when P-values were <0.05.
Results
Animal studies
Animal data. Body weight increased in all the three
groups, but increased more in C (423±5g) than in DM
(274±4 g)andDMþ I rats (356±7g) (P<0.01).Kidney
weight was measured at the time of sacriﬁce. Kidney
weight and the ratio of kidney weight to body weight in
DM rats (3.09±0.10 g and 1.13±0.05%, respectively)
were signiﬁcantly higher than those in C rats (2.78±
0.06 g and 0.66±0.02%, respectively) (P<0.05).
The mean blood glucose levels of C, DM and DMþ I
rats were 97.8±2.2, 466.5±5.2 and 254.2±3.8mg/dl,
respectively (P<0.01). Compared with the C group
(0.32±0.02mg/day), 24 h urinary albumin excretion
at 6 weeks was signiﬁcantly higher in DM rats
(1.18±0.11mg/day, P<0.05) (Table 1).
Rat P-cadherin sequence. The PCR product
ampliﬁed using cDNA of rat glomeruli and primers
designed on the area where human and mouse
P-cadherin showed homology was extracted from the
gel and sequenced with ALFexpress DNA sequencer
(Amersham Pharmacia Biotech AB, Uppsala, Sweden).
The partial rat P-cadherin sequence, excluding the
primer regions, was compared with human and mouse
P-cadherin sequences. Rat P-cadherin showed 90.7%
homology with mouse P-cadherin and 84.2% homol-
ogy with human P-cadherin (Figure 1).
Glomerular P-cadherin mRNA and protein
expression. For the animal studies, we examined
whether glomerular P-cadherin mRNA and protein
expressions were altered in DM rats and whether the
changes in P-cadherin expression were associated
with the development of albuminuria. Glomerular
P-cadherin mRNA was signiﬁcantly lower in DM
(1.36±0.20 102 attm/ng RNA) than C rats
(2.61±0.33 102 attm/ng RNA) (P<0.05) at 6 weeks
after induction of DM, while the amount in the
DMþ I was intermediate (2.27±0.32 102 attm/ng
RNA) (Figures 2A and 2B). In contrast, there was no
signiﬁcant difference in the amount of glomerular
GAPDH mRNA among the three groups (data not
shown). Even when corrected for GAPDH mRNA,
glomerular P-cadherin mRNA remained signiﬁcantly
lower in DM compared with C (P-cadherin/GAPDH:
0.51±0.06 101 vs 1.16±0.21 101; P<0.05).
Figure 3 shows a representative western blot of
equal amounts of protein from the lysates of sieved C,
DM and DMþ I glomeruli at 6 weeks. Glomerular
P-cadherin protein expression was also decreased in
DM compared with C and DMþ I rats as P-cadherin
mRNA expression. Densitometric quantitation
revealed that there was a 67% decrease in P-cadherin
protein expression in DM relative to C rats (P<0.01),
with no difference in b-actin protein expression.
Pathology. Immunoﬂuorescence staining for glomer-
ular P-cadherin conﬁrmed the mRNA and western blot
ﬁndings. There was a signiﬁcant decrease in glomerular
P-cadherin expression, which exhibited linear/punctate
distribution along the glomerular capillary loops, in
DM rats. The decrease in P-cadherin expression in DM
glomeruli was ameliorated by insulin treatment. The
semi-quantitative score for immunoﬂuorescence inten-
sity for P-cadherin was signiﬁcantly lower in DM
compared with C (P<0.01) and DMþ I glomeruli
(P<0.05) (Figures 4A and 4B). In contrast, there was
no statistical difference in mean podocyte counts per
glomerulus assessed by WT-1 staining among the three
Table 1. Body weight, kidney weight, kidney weight/body weight, blood glucose and 24 h urinary albumin excretion of the three groups
Control (n¼ 8) DM (n¼ 8) DMþ I (n¼ 8)
Body weight after 6 weeks (g) 423±5 274±4a 356±7a,b
Kidney weight (g) 2.78±0.06 3.09±0.10c 2.81±0.08
Kidney wt/body wt (%) 0.66±0.02 1.13±0.05c 0.79±0.04d
Blood glucose (mg/dl) 97.8±2.2 466.5±5.2a 254.2±3.8a,b
24 h urinary albumin excretion (mg/day) 0.32±0.02 1.18±0.11c 0.62±0.08d
aP<0.01 vs control.
bP<0.01 vs DM.
cP<0.05 vs control.
dP<0.05 vs DM.
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groups (C: 15.8±1.8; DM: 15.3±1.9; DMþ I:
16.1±2.0).
Podocyte culture studies
P-Cadherin mRNA and protein expression. The
P-cadherin mRNA of podocytes exposed to HG was
signiﬁcantly lower than that of podocytes in LG
media (HG: 0.89±0.10 102 attm/ng RNA; LG:
1.58±0.28 102 attm/ng RNA; P<0.05) and this
HG-induced decrement in P-cadherin mRNA expres-
sion was ameliorated by the PKC inhibitors calphostin
C (1.39±0.22 102 attm/ng RNA) or GF 109203X
(1.32±0.32 102 attm/ng RNA) (Figure 5). On the
other hand, there was no signiﬁcant difference in the
amount of GAPDH mRNA (data not shown).
After correction for GAPDH mRNA, the differences
in P-cadherin mRNA expression remained signi-
ﬁcant (P-cadherin/GAPDH: 2.69± 0.26 102 vs
1.52±0.25102; P<0.01).
The P-cadherin protein expression also was signiﬁ-
cantly lower in HG than in LG podocytes. There was
a 62% decrease in P-cadherin protein expression in
HG compared with LG cells assessed by densitom-
etry (P<0.05) and PKC inhibitor nearly normalized
Fig. 1. The partial nucleotide sequence of rat P-cadherin. Rat P-cadherin showed 90.7% homology with mouse P-cadherin and 84.2%
homology with human P-cadherin. The grey box indicates the unconserved nucleotide shared by rat and mouse or by rat and human. The
nucleotides used as primers for RT–PCR are underlined.
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Fig. 2. Glomerular P-cadherin and GAPDH mRNA expressions
in C and DM rats. (A) A representative P-cadherin competitive
RT–PCR electrophoresis of C, DM and DMþ I glomeruli at
6 weeks after DM induction (n¼ 8). Each lane represents a
competitive RT–PCR reaction (45 cycles) with a ﬁxed amount of
P-cadherin wild-type cDNA (397 bp) from the equivalent of 50 ng
RNA and a variable amount of P-cadherin competitor cDNA (279
bp) as follows: (lane 1) 0.5 attm/ml, (lane 2) 0.1 attm/ml, (lane 3)
0.05 attm/ml, (lane 4) 0.01 attm/ml and (lane 5) 0.005 attm/ml. (B) A
signiﬁcant decrement in glomerular P-cadherin mRNA expression
was observed in DM vs C rats. *P<0.05 vs C and DMþ I.
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Fig. 3. A representative P-cadherin western blot of C, DM and
DMþ I glomeruli at 6 weeks after DM induction. Densitometric
quantitation revealed that there was a 67% decrease in P-cadherin
protein expression in DM relative to C rats (P<0.01), whereas
there was no difference in b-actin protein expression.
ControlA DM DM+I
Wild type (397 bp)
Competitor (279 bp)
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this HG-induced reduction in P-cadherin protein
expression (Figure 6).
Mannitol (19.4mM) had no effect on the P-cadherin
mRNA and protein expression of podocytes.
Discussion
Diabetic nephropathy is characterized pathologically
by glomerular and tubular hypertrophy and increased
extracellular matrix accumulation and clinically by
proteinuria. The underlying pathological change
responsible for proteinuria in various glomerular
diseases is the loss of size-selective and/or charge-
selective properties of the glomerular ﬁltration barrier
[2], which is comprised of glomerular endothelium,
basement membrane and podocytes connected by a slit
diaphragm. In this study, we demonstrate for the ﬁrst
time that P-cadherin mRNA and protein expression are
decreased in experimental diabetic glomeruli and in
high-glucose-stimulated podocytes, suggesting a poten-
tial role for P-cadherin loss in the development of
proteinuria in early diabetic nephropathy.
It has been suggested that changes in these glomer-
ular ﬁltration barrier-associated molecules play critical
roles in the contribution to the pathogenesis of
proteinuria in glomerular disease. Based on this view,
there have been several reports on the changes of these
ﬁltration barrier-associated molecules in various kinds
of kidney diseases, but most of the previous studies
were focused on changes in nephrin [10–12], a product
of the NPHS1 gene, which is mutated in patients with
congenital nephrotic syndrome of the Finnish type [13].
Since proteinuria is a cardinal feature of diabetic
nephropathy, the contribution of changes in nephrin
expression to proteinuria in diabetic nephropathy has
also been studied, but the results were not consistent.
Bonnet et al. [12] demonstrated a reduction in both
mRNA and protein expression of nephrin in diabetic
spontaneously hypertensive rats, whereas Aaltonen
et al. [11] observed an increase in nephrin mRNA
levels in streptozotocin-induced diabetic rats and in
non-obese diabetic mice even before signiﬁcant albu-
minuria developed. The reasons for the divergence of
changes in nephrin expression in diabetic nephropathy
may be due to a variety of underlying causes, including
but not limited to species differences, differences in
diabetes duration or accompanied hypertension.
P-Cadherin is one of the classical cadherins, a
superfamily of glycoproteins involved in cell–cell
adhesion, and is known to exist in the basal cells of
skin and prostate, in the myoepithelial cells of the
mammary gland and in the glomerular slit diaphragm
[4,6]. Based on the location of P-cadherin at the slit
diaphragm, it has been proposed that P-cadherin serves
as a basic scaffold for the slit diaphragm, whereas
the permselectivity is provided by the slit diaphragm
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Fig. 6. Western blot of P-cadherin in podocytes exposed to LG and
HG for 5 days (representative of ﬁve blots). P-Cadherin protein
expression was signiﬁcantly lower in podocytes exposed to HG than
in those exposed to LG. Densitometric quantitation revealed that
there was a 62% decrease in P-cadherin protein expression in
podocytes cultured under HG conditions vs those cultured under
LG conditions (P<0.05) and this HG-induced decrement in
P-cadherin protein expression was ameliorated by PKC inhibitor,
107M calphostin C (CC) or 106M GF 109203X (GFX).
Mannitol (M) had no effect on the P-cadherin protein expression
of podocytes.
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Fig. 5. P-Cadherin and GAPDH mRNA expressions in podocytes
exposed to LG, LGþM or HG medium with or without PKC
inhibitor, 107M calphostin C (CC) or 106M GF 109203X (GFX)
(n¼ 5). A signiﬁcant decrement in P-cadherin mRNA expression
was observed in HG cells compared with LG cells and this HG-
induced decrement in P-cadherin mRNA expression was amelio-
rated by PKC inhibitor. Mannitol (M) had no effect on the
P-cadherin mRNA expression of podocytes. *P<0.05 vs LG and
HGþPKC inhibitor.
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Fig. 4. Immunoﬂuorescence staining for P-cadherin protein in C,
DM and DMþ I glomeruli at 6 weeks after DM induction.
(A) There was a signiﬁcant decrease in glomerular P-cadherin
expression, which exhibited linear/punctate distribution along the
glomerular capillary loops, in DM rats. The decrease in P-cadherin
expression in DM glomeruli was ameliorated by insulin treatment.
(Magniﬁcation: 400.) (B) Semi-quantitative immunoﬂuorescence
score for glomerular P-cadherin was signiﬁcantly lower in DM
compared with C rats. *P<0.01 vs C; #P<0.05 vs DM.
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complex composed of P-cadherin and other proteins,
such as nephrin [4]. In contrast to nephrin, the role of
P-cadherin in the pathogenesis of proteinuria has been
studied less. Bains et al. [10] failed to demonstrate
any changes of cadherin, including P-cadherin protein
expression, using Pan-cadherin antibody in patients
with minimal change nephrotic syndrome and
membranous glomerulonephritis assessed by indirect
immunoﬂuorescence microscopy. Because cadherin
was not detected in either the normal or the diseased
glomeruli by indirect immunoﬂuorescence, it was
difﬁcult to identify minor changes of cadherin expres-
sion in proteinuric patients. In congenital Finnish type
nephrotic kidney, P-cadherin was expressed normally
in spite of absent slit diaphragms [14]. In addition, even
though proteinuria was not investigated in P-cadherin-
deﬁcient mice, it seemed that life-threatening protein-
uria did not develop in view of the survival of these mice
[15]. In contrast, a more recent study demonstrated
that intravenous injection of anti-P-cadherin antibody
resulted in a 49% increase in 24 h urinary protein
excretion independent of nephrin or NEPH1 [16],
suggesting that P-cadherin also serves as a glomerular
ﬁltration barrier to protein. As described previously,
the mRNA expression of nephrin was increased rather
than decreased in early diabetic nephropathy [11]
and, in the present study, we demonstrated a decrease
in P-cadherin mRNA and protein expression in 6-week-
old diabetic glomeruli. Therefore, the potential role of
P-cadherin in the development of proteinuria in
diabetes may not be an irrelevant ﬁnding and it seems
likely that the molecular changes of the slit diaphragm
complex, and not a single slit diaphragm-associated
molecule, might contribute to the development of
proteinuria in diabetic nephropathy.
The numbers of glomerular podocytes are known
to decrease in type 1 diabetic patients of all ages, with
reduced podocyte numbers even in diabetes of short
duration [17]. Analysis of kidney biopsies from Pima
Indians with type 2 diabetes also demonstrated that
subjects with clinical nephropathy exhibited broad-
ening of podocyte foot processes associated with a
reduction in the number of podocytes per glomerulus
[18]. Focal detachment of podocytes from the GBM
may be associated with a decrease in a3b1 integrin at
the podocyte basal plasma membrane, which occurs as
early as 1 month after the onset of hyperglycaemia [19].
In the present study, P-cadherin mRNA expression was
signiﬁcantly decreased in HG-stimulated podocytes,
whereas there was no difference in GAPDH mRNA
expression. In addition, immunoﬂuorescence micro-
scopy revealed a reduction of P-cadherin staining, both
in intensity and area, in diabetic glomeruli with no
signiﬁcant difference in podocyte numbers assessed by
WT-1 staining. These ﬁndings suggest that the reduc-
tion of P-cadherin mRNA and protein expression in
early diabetic conditions is not attributed to the
decrease in podocyte numbers.
Besides their basic role in cell–cell adhesion,
cadherins appear to be involved in cellular signalling
and differentiation [6]. Since little is known about
the role of P-cadherin in signal transduction in the
glomerular podocytes, it is uncertain whether the
decrease in P-cadherin expression under diabetic
conditions is a direct cause of proteinuria in diabetic
nephropathy or a coincident change associated with
the signal transduction pathway. Numerous studies
have revealed that PKC is activated in diabetic
conditions, in vivo and in vitro [20]. In addition, the
PKC pathway is a key signal pathway associated
with the activation of transforming growth factor-b1
and ﬁbronectin synthesis, which are important in
the pathogenesis of diabetic nephropathy [20]. In this
study, P-cadherin expression was decreased in cells
exposed to HG and this decrement was ameliorated
by the PKC inhibitor, suggesting that P-cadherin
expression is closely linked to activation of the PKC
pathway.
To conclude, in diabetes in vivo and in podocytes
cultured in HG, P-cadherin mRNA and protein expres-
sions are decreased and PKC seems to be involved in
HG-induced down-regulation of P-cadherin expres-
sion. In addition, the changes in glomerular P-cadherin
expression are associated with the development of
albuminuria in diabetic rats. Taken together, the data
suggest that alterations in P-cadherin in podocytes
are related to early changes of diabetic nephropathy
and, thus, may contribute to the development of
proteinuria.
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